Polynovo (ASX:PNV) Research & Development: A$5.8 Mil (TTM As of Dec. 2025)


ASX:PNV Polynovo Ltd ASX:PNV
76 GF Score
Price A$0.91
GF Value A$3.24
Valuation Significantly Undervalued
! 4 Warning Signs
View Full Analysis

What is Polynovo Research & Development?

Polynovo ASX:PNV -3.70% 76 Research & Development is A$5.8 Mil as of Dec. 2025. GuruFocus rates ASX:PNV with a GF Score™ of 76/100 and a GF Value™ of A$3.24 (Significantly Undervalued). The stock has 4 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Polynovo's Research & Development for the six months ended in Dec. 2025 was A$2.4 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 was A$5.8 Mil.

Polynovo  (ASX:PNV) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Polynovo Research & Development Related Terms

Polynovo Research & Development Historical Data

* Premium members only.

The historical data trend for Polynovo's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Polynovo Research & Development Chart

Polynovo Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.65 5.75 7.43 10.93 8.46

Polynovo Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.87 6.06 5.06 3.40 2.44
ASX:PNV
76GF Score
Polynovo Ltd ASX:PNV
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Polynovo Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$5.8 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of A$5.8 Mil mean?
Polynovo (ASX:PNV) has a Research & Development of A$5.8 Mil as of Dec. 2025. Research and development expense is the total cost for research and development activities. View historical data on Polynovo and its competitors.
Is Polynovo's Research & Development too high?
Polynovo's current Research & Development is A$5.8 Mil. Overall, Polynovo has a GF Score™ of 76/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Polynovo's Research & Development compare to ABT and SYK?
Polynovo's Research & Development of A$5.8 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Medical Devices & Instruments company?
A good Research & Development depends on the Medical Devices & Instruments industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Polynovo and its competitors. Polynovo's current Research & Development is A$5.8 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Polynovo stock overvalued right now?
Based on GuruFocus' analysis, Polynovo (ASX:PNV) is currently considered Significantly Undervalued. The stock's GF Value™ is A$3.24, compared to a current price of A$0.91 — trading 71.9% below its estimated fair value. The current Research & Development is A$5.8 Mil. Polynovo's overall GF Score™ is 76/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Polynovo (ASX:PNV), the current Research & Development is A$5.8 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Polynovo (ASX:PNV) Overvalued in 2026?

Based on GuruFocus' analysis, Polynovo stock appears to be undervalued. The current stock price of A$0.91 is trading 71.9% below its estimated GF Value™ of A$3.24. GuruFocus considers Polynovo to be Significantly Undervalued.

Key valuation signals for ASX:PNV:

  • Research & Development: A$5.8 Mil
  • GF Value™: A$3.24 vs. price of A$0.91 (71.9% below fair value)
  • GF Score™: 76/100 with 4 warning signs

No single metric tells the full story. See the ASX:PNV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Polynovo Business Description

Other Exchanges CALZF:USAMFJ:Germany
Address 320 Lorimer Street, Unit 2, Port Melbourne, VIC, AUS, 3207
Polynovo earns most of its revenue from US sales of its NovoSorb Biodegradable Temporizing Matrix, or NovoSorb BTM. The product is a patented biodegradable synthetic scaffold to support the regeneration of the dermis when lost through surgery, trauma, burns, or other causes of tissue loss. Once the product is applied to a wound, it takes a few weeks for the dermal layer to fully integrate within the polymer scaffold before a clinician can delaminate the outer layer. A small wound would then close either naturally or with a dressing, while a larger wound would close through a split-skin graft or alternative product such as Avita's RECELL. NovoSorb BTM then slowly degrades to harmless byproducts which are fully absorbed in roughly 18 months.
76GF Score

Get the complete analysis for ASX:PNV

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.91
Price
A$3.24
GF Value